These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 19838194)
41. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920 [TBL] [Abstract][Full Text] [Related]
42. An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression. Yano M; Imamura T; Asai D; Moriya-Saito A; Suenobu S; Hasegawa D; Deguchi T; Hashii Y; Kawasaki H; Hori H; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Matsumoto K; Kiyokawa N; Oda M; Sato A; Genes Chromosomes Cancer; 2014 Oct; 53(10):815-23. PubMed ID: 24935070 [TBL] [Abstract][Full Text] [Related]
43. Correlation of the surface expression of thymic stromal lymphopoietin receptor with the presence of CRLF2 gene rearrangements in children with B-lineage acute lymphoblastic leukemia. Demina I; Zerkalenkova E; Soldatkina O; Kazakova A; Semchenkova A; Goncharova M; Novichkova G; Maschan M; Karachunskiy A; Olshanskaya Y; Popov A Int J Lab Hematol; 2023 Jun; 45(3):337-343. PubMed ID: 36748719 [TBL] [Abstract][Full Text] [Related]
44. CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome. Junco JJ; Zorman B; Gant VU; Muñoz J; Lacorazza HD; Sumazin P; Rabin KR Exp Hematol; 2022 Jun; 110():34-38. PubMed ID: 35306048 [TBL] [Abstract][Full Text] [Related]
45. GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Madzio J; Pastorczak A; Sedek L; Braun M; Taha J; Wypyszczak K; Trelinska J; Lejman M; Muszynska-Roslan K; Tomasik B; Derwich K; Koltan A; Kazanowska B; Irga-Jaworska N; Badowska W; Matysiak M; Kowalczyk J; Styczynski J; Fendler W; Szczepanski T; Mlynarski W Genes Chromosomes Cancer; 2019 Sep; 58(9):619-626. PubMed ID: 30859636 [TBL] [Abstract][Full Text] [Related]
46. Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients. Page EC; Heatley SL; Yeung DT; Thomas PQ; White DL Cancer Lett; 2018 Sep; 432():69-74. PubMed ID: 29879498 [TBL] [Abstract][Full Text] [Related]
47. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort. Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401 [TBL] [Abstract][Full Text] [Related]
48. Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia. Vesely C; Frech C; Eckert C; Cario G; Mecklenbräuker A; Zur Stadt U; Nebral K; Kraler F; Fischer S; Attarbaschi A; Schuster M; Bock C; Cavé H; von Stackelberg A; Schrappe M; Horstmann MA; Mann G; Haas OA; Panzer-Grümayer R Leukemia; 2017 Jul; 31(7):1491-1501. PubMed ID: 27899802 [TBL] [Abstract][Full Text] [Related]
49. Gain of chromosome 21 increases the propensity for Page EC; Heatley SL; Rehn J; Thomas PQ; Yeung DT; White DL Front Oncol; 2023; 13():1177871. PubMed ID: 37483494 [TBL] [Abstract][Full Text] [Related]
50. [Down syndrome and acute lymphoblastic leukemia]. Okamoto Y Rinsho Ketsueki; 2021; 62(10):1465-1473. PubMed ID: 34732618 [TBL] [Abstract][Full Text] [Related]
51. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Herold T; Schneider S; Metzeler KH; Neumann M; Hartmann L; Roberts KG; Konstandin NP; Greif PA; Bräundl K; Ksienzyk B; Huk N; Schneider I; Zellmeier E; Jurinovic V; Mansmann U; Hiddemann W; Mullighan CG; Bohlander SK; Spiekermann K; Hoelzer D; Brüggemann M; Baldus CD; Dreyling M; Gökbuget N Haematologica; 2017 Jan; 102(1):130-138. PubMed ID: 27561722 [TBL] [Abstract][Full Text] [Related]
52. Targeting signaling pathways in acute lymphoblastic leukemia: new insights. Harrison CJ Hematology Am Soc Hematol Educ Program; 2013; 2013():118-25. PubMed ID: 24319172 [TBL] [Abstract][Full Text] [Related]
53. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia. Tasian SK; Loh ML Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304 [TBL] [Abstract][Full Text] [Related]
54. Clinical, biological, and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol. Wang Y; Li J; Xue TL; Tian S; Yue ZX; Liu SG; Gao C Eur J Haematol; 2023 Jun; 110(6):669-679. PubMed ID: 36814093 [TBL] [Abstract][Full Text] [Related]
59. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Roberts KG; Morin RD; Zhang J; Hirst M; Zhao Y; Su X; Chen SC; Payne-Turner D; Churchman ML; Harvey RC; Chen X; Kasap C; Yan C; Becksfort J; Finney RP; Teachey DT; Maude SL; Tse K; Moore R; Jones S; Mungall K; Birol I; Edmonson MN; Hu Y; Buetow KE; Chen IM; Carroll WL; Wei L; Ma J; Kleppe M; Levine RL; Garcia-Manero G; Larsen E; Shah NP; Devidas M; Reaman G; Smith M; Paugh SW; Evans WE; Grupp SA; Jeha S; Pui CH; Gerhard DS; Downing JR; Willman CL; Loh M; Hunger SP; Marra MA; Mullighan CG Cancer Cell; 2012 Aug; 22(2):153-66. PubMed ID: 22897847 [TBL] [Abstract][Full Text] [Related]
60. Philadelphia chromosome-like acute lymphoblastic leukemia with concomitant rearrangements of CRLF2 and ABL1: a pediatric case report. He GQ; Lei YP; Huang DW; Gao J; Yang R BMC Pediatr; 2024 Aug; 24(1):517. PubMed ID: 39127642 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]